PredxBio

Executive Summary

PredxBio is a San Francisco-based startup leveraging explainable AI and spatial multi-omics to transform drug discovery and development. Founded in 2020, the company provides biopharma teams with decision-ready insights from complex tissue data, enabling more informed choices in drug target identification, patient stratification, and biomarker discovery. By combining tissue intelligence with advanced machine learning, PredxBio aims to reduce the high failure rates in clinical trials and accelerate the delivery of effective therapies. As a private company without disclosed funding or revenue, PredxBio operates in the competitive AI-driven diagnostics space, targeting the growing demand for precision medicine solutions. Its technology addresses a critical bottleneck in drug development: the ability to extract actionable insights from high-dimensional spatial data. With no publicly announced partnerships or product launches, the company remains in an early-stage growth trajectory, relying on its unique value proposition to attract potential collaborators and investors.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Announcement60% success
• H1 2027First Major Biopharma Partnership50% success
• Q2 2027Product Launch or Platform Update45% success